1.Du Z, et a.. Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults. Nat Med. 2025 Jan 9. 2.Walsh EE, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16)...
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complicati
VACCINE effectivenessVIRAL vaccinesThis study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.Surie, DiyaSelf, Wesley H.Zhu, Yuwei
Older adults aren't the only group impacted by RSV. Very young children have been at the center of this winter's unusually severe RSV surge, which is now seeingcasesclimbing down from a steep peak. Pfizer also has amaternal vaccinein the race, which would be given to parents-to-be in ...
Promising Top-Line Results for RSV Vaccine in Immunocompromised Adults Samantha Anderer JAMA. 2024;332(13):1043. doi:10.1001/jama.2024.17607 Full Text Pfizer’s ABRYSVO vaccine was safe and generated a strong immune response against respiratory syncytial virus (RSV) in immunocompromised adults...
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
参考来源:‘US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease. News release. Pfizer.注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。如有需要可以咨询一下香港登越药业,专业提供各类进出口服务。 送TA礼物 1楼2025-02-...
RSV in Older Adults If you’re an older adult, RSV can be more dangerous. If you’re 75 or older, your doctor may recommend a single dose of the RSV vaccine toprevent problems. Experts also recommend a single dose of the vaccine for adults 60 to 74 years old and up who are at hig...
The vaccine, made by the pharmaceutical company GSK, is for older adults. Pfizer and Moderna are also developing similar RSV vaccines. The Centers for Disease Control and Prevention still needs to weigh in with specific recommendations, which is expected in June. GSK anticipates it will have eno...
(NEW YORK) — Moderna’s respiratory syncytial virus, or RSV, vaccine for older adults was about 84% effective at preventing serious illness, according to data from a late-stage trial published Tuesday. Adult patients in the clinical trial appeared to tolerate the vaccine well and there were...